Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Roche Glycart Ag patents


Recent patent applications related to Roche Glycart Ag. Roche Glycart Ag is listed as an Agent/Assignee. Note: Roche Glycart Ag may have other listings under different names/spellings. We're not affiliated with Roche Glycart Ag, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "R" | Roche Glycart Ag-related inventors


Aspgr antibodies and uses thereof

The present invention generally relates to antibodies specific for asialoglycoprotein receptor (asgpr) and their use for selectively delivering effector moieties that influence cellular activity. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. ... Roche Glycart Ag

Bispecific t cell activating antigen binding molecules

The present invention generally relates to novel bispecific antigen binding molecules for t cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. ... Roche Glycart Ag

Anti-cea antibodies

The present invention provides antigen binding molecules (abms) which bind membrane-bound cea, including abms with improved therapeutic properties, and methods of using the same.. . ... Roche Glycart Ag

Interleukin-2 fusion proteins and uses thereof

The present invention generally relates to fusion proteins of immunoglobulins and interleukin-2 (il-2). In addition, the present invention relates to polynucleotides encoding such fusion proteins, and vectors and host cells comprising such polynucleotides. ... Roche Glycart Ag

Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases

The present invention relates to bispecific antibody against human vascular endothelial growth factor (vegf/vegf-a) and against human angiopoietin-2 (ang-2) of human igg1 or igg4 subclass with mutations i253a, h310a, and h435a, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. . ... Roche Glycart Ag

Bispecific antigen binding molecules

The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. ... Roche Glycart Ag

Anti-her3 antibodies and uses thereof

The present invention relates to antibodies binding to human her3 (anti-her3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.. . ... Roche Glycart Ag

Method and constructs for the ph dependent passage of the blood-brain-barrier

Herein is reported a fusion polypeptide comprising i) at least one binding site, e.g. Which comprises an antibody heavy chain variable domain and an antibody light chain variable domain, and which binds to an internalizing cell surface receptor, and ii) at least one pharmaceutically active compound, whereby the ec50-value of the binding pair that binds to an internalizing cell surface receptor determined at ph 5.5 is higher than the ec50-value of the same binding pair determined at ph 7.4 and its use for delivering a pharmaceutically active compound across the blood-brain-barrier.. ... Roche Glycart Ag

Antibody fc variants

The invention relates to engineered polypeptides comprising fc variants and their uses. More specifically, fc variants are described exhibiting reduced effector function. ... Roche Glycart Ag

A-fucosylation detection in antibodies

This invention describes a new analytical method to determine the quantity and distribution of fucose per fc within an antibody preparation.. . ... Roche Glycart Ag

Novel immunoconjugates

The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an fc domain and a single effector moiety. ... Roche Glycart Ag

Combination il-2 immunoconjugate therapy

The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.. ... Roche Glycart Ag








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Roche Glycart Ag in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Roche Glycart Ag with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###